Dynavax prelims, update

 

• Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million
• Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025
• New $30 million contract with U.S. Department of Defense to advance plague vaccine program
• Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024

https://www.prnewswire.com/news-releases/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highlights-302349069.html